Sign in to view content

Brolucizumab in HAWK/HARRIER: Outcomes, Efficacy, & Dosing Status – Everything You Need to Know!

David M. Brown, MD

Video
Published 2018

Related

Phase 3 Randomized, Double-Masked Studies of Brolucizumab Versus Aflibercept in nAMD: Expanded Primary and Secondary Outcomes From HAWK/HARRIER
Arshad M. Khanani, MD, MA, FASRS
Annual Meeting Talks
2018
Factors Associated with Worsening Proliferative Diabetic Retinopathy
Carl W. Baker, MD, FASRS
Updates from the Field
2017
First Results From a Phase 1B Multiple-Dose Study of KSI-301: A Novel Anti-VEGF Antibody Biopolymer Conjugate (ABC) With Extended Durability
Pravin U. Dugel, MD
Annual Meeting Talks
2019

Category: AMD-Neovascular

See more